Arkolith/Insider Trading/GTHX/Form 4

Umstead John W. V

Chief Financial OfficerG1 Therapeutics, Inc. (GTHX) · full profile →Form 4 · filed Mar 22, 2024
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 20, 2024Grant(A)38K—$0161K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001562180-24-002948) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML